Tri Chemical Laboratories (4369) Q4 2025 earnings summary

Executive summary

• Achieved record high net sales and profits for FY2024, recovering from the prior year's memory market downturn.

• Net sales rose 68.1% year-over-year to ¥18,905 million for the fiscal year ended January 31, 2025.

• Operating profit increased 169.8% to ¥5,256 million; ordinary profit up 100.9% to ¥6,583 million.

• Profit attributable to owners of parent more than doubled to ¥4,961 million, up 100.8% year-over-year.

• Comprehensive income reached ¥4,992 million, an 87.0% increase year-over-year.

Financial highlights

• Gross profit improved to ¥8,012 million from ¥4,086 million year-over-year.

• Operating margin rose to 27.8% from 17.3% year-over-year.

• Basic earnings per share increased to ¥152.69 from ¥76.03 year-over-year.

• Total assets increased to ¥36,944 million, with shareholders' equity at ¥30,748 million.

• Cash and cash equivalents at period end were ¥9,439 million.

Outlook and guidance

• FY2025 net sales forecast at ¥26,000 million (+37.5%), operating profit at ¥6,050 million (+15.1%).

• Ordinary profit expected to reach ¥6,900 million, net profit ¥5,000 million.

• Dividend per share is forecast at ¥35.00 for the next fiscal year.

• Medium-term plan targets net sales of ¥31,500 million and operating profit of ¥8,620 million by FY2027.

• Growth driven by continued strong demand in China and new plant operations.